← All trials
NCT05169710
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2021
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Dec 27, 2021
- Last posted
- Dec 7, 2022
- Enrollment
- 522
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sumitomo DainipponLead sponsor
- Sumitomo DainipponStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.